Asset Details
Do you wish to reserve the book?
Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role
Do you wish to request the book?
Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adjunctive Thalidomide Therapy of Childhood Tuberculous Meningitis: Possible Anti-Inflammatory Role
2000
Overview
The objective of this study was to determine the safety and tolerability of the immunomodulatory agent thalidomide as adjunct therapy in children with tuberculous meningitis. Children with stage 2 tuberculous meningitis received oral thalidomide for 28 days in a dose-escalating study, in addition to standard four-drug antituberculosis therapy, corticosteroids, and specific treatment of complications such as raised intracranial pressure. Clinical and laboratory evaluations were carried out. Fifteen patients (median age, 34 months) were enrolled. Thalidomide was administered via nasogastric tube in a dosage of 6 mg/kg/day, 12 mg/kg/day, or 24 mg/kg/day. The only adverse events possibly related to the study drug were transient skin rashes in two patients. Levels of tumor necrosis factor-α in the cerebrospinal fluid decreased markedly during thalidomide therapy. Clinical outcome and neurologic imaging showed greater improvement than that experienced with historical controls. Thalidomide appeared safe and well tolerated in children with stage 2 tuberculous meningitis and could have important anti-inflammatory effects. These promising results have led us to embark on a randomized, double-blind, placebo-controlled trial of the efficacy of thalidomide in tuberculous meningitis. (J Child Neurol 2000;15:497-503).
Publisher
SAGE Publications
Subject
Adjuvants, Immunologic - adverse effects
/ Adjuvants, Immunologic - pharmacology
/ Adjuvants, Immunologic - therapeutic use
/ Antitubercular Agents - therapeutic use
/ Biomarkers - cerebrospinal fluid
/ Child
/ Female
/ Humans
/ Infant
/ Inflammation - cerebrospinal fluid
/ Male
/ Mycobacterium tuberculosis - isolation & purification
/ Thalidomide - adverse effects
/ Thalidomide - therapeutic use
/ Tuberculosis, Meningeal - cerebrospinal fluid
/ Tuberculosis, Meningeal - diagnostic imaging
